| Identification | Back Directory | [Name]
A-METHYL-DL-P-TYROSINE | [CAS]
658-48-0 | [Synonyms]
h9/88
MK-781
α-Methyl-p-tyrosine
DL-α-Methyltyrosine
alpha-methyl-tyrosin
α-Methylparatyrosine
A-METHYL-DL-P-TYROSI
A-METHYL-DL-P-TYROSINE
DL-2-METHYL-4-TYROSINE
alpha-methyl-p-tyrosine
DL-alpha-Methyltyrosine
Tyrosine, .alpha.-methyl-
alpha-methyl-para-tyrosine
DL-alpha-Methyltyrosine,98%
DL-alpha-Methyltyrosinealpha-MT
2-P-HYDROXYPHENYLMETHYL-DL-ALANINE
DL-2-Methyl-3-(4-hydroxyphenyl)alanine, AMPT
2-Amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
α-Amino-β-(4-hydroxyphenyl)-α-methylpropionic acid
2-Amino-3-(4-hydroxy-phenyl)-2-methyl-propionic acid
(S)-2-AMino-3-(4-hydroxyphenyl)-2-Methylpropanoic acid | [EINECS(EC#)]
211-523-0 | [Molecular Formula]
C10H13NO3 | [MDL Number]
MFCD00004187 | [MOL File]
658-48-0.mol | [Molecular Weight]
195.215 |
| Chemical Properties | Back Directory | [Appearance]
off-white fine powder | [Melting point ]
>300 °C(lit.)
| [Boiling point ]
331.88°C (rough estimate) | [density ]
1.1926 (rough estimate) | [refractive index ]
1.5150 (estimate) | [storage temp. ]
−20°C | [solubility ]
Aqueous Acid (Sparingly), Aqueous Base, Water (Slightly) | [form ]
Solid | [pka]
2.29±0.16(Predicted) | [color ]
White to Off-White | [BRN ]
2938704 | [EPA Substance Registry System]
.alpha.-Methyltyrosine (658-48-0) |
| Hazard Information | Back Directory | [Chemical Properties]
off-white fine powder | [Uses]
A tyrosine hydroxylase inhibitor. An antihypertensive in pheochromocytoma. | [reaction suitability]
reaction type: solution phase peptide synthesis | [in vivo]
α-Methyl-p-tyrosine (250 mg/kg, intraperitoneal injection, single dose) can exacerbate the severity and duration of tonic and clonic seizures induced by Pentylenetetrazol in male CFI mice[2]. | Animal Model: | Pentylenetetrazol (PTZ)-induced epilepsy CFI strain mouse model (15-25 g) | | Dosage: | 250 mg/kg | | Administration: | Intraperitoneal injection (i.p.), single dose, PTZ administered 8 hours after α-Methyl-p-tyrosine injection? | | Result: | Increased the severity and duration of seizures, especially enhancing tonic and clonic seizures induced by PTZ. |
|
|
|